Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

NCT03680560 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

Solid Tumor
HER-2 Protein Overexpression

Interventions

BIOLOGICAL: ACTR T Cell Product
DRUG: Trastuzumab

Sponsor

Cogent Biosciences, Inc.